Skip to main content
Erschienen in: Clinical Rheumatology 6/2003

01.12.2003 | Original Article

Patterns of pain in Paget’s disease of bone and their outcomes on treatment with pamidronate

verfasst von: Sreekanth Vasireddy, Amruta Talwalkar, Hazel Miller, Rakesh Mehan, David R. Swinson

Erschienen in: Clinical Rheumatology | Ausgabe 6/2003

Einloggen, um Zugang zu erhalten

Abstract

Two-thirds of patients with Paget’s disease seeking medical attention present with pain. We studied patterns of pagetic pain in relation to physical activity, and the effect of coexistent osteoarthritis (OA)/pagetic arthropathy on pain and physical activity before and after treatment with pamidronate. Patients with lower-segment Paget’s disease (lumbar spine, pelvis or lower limbs), raised alkaline phosphatase (ALP), and pain as a symptom were included. Two subgroups were identified based on the absence (P group), or presence (POA group) of radiological OA in the lower segment. They received 2–4 fortnightly infusions of pamidronate 30–60 mg and were followed up at 6 weeks, 3 months and 6 months. Outcome measures were visual analog scales for pain at rest, on standing, on walking and at night; standing time, walking distance, 50-yard walking time, and ALP. Twenty-five patients (12 men, 13 women, mean age 70.1±1.9 years), received a mean of 142±9.7 mg of pamidronate. The P group had higher mean ALP (p=0.003) and higher scores for pain (not significant) at baseline than the POA group. Compared to baseline, P group had significant improvements (p<0.01) at 6 months in rest pain, standing pain and walking pain. The POA group had non-significant changes in pain at 6 months. ALP improved significantly at 6 months in both subgroups (p<0.01). The whole group also improved at 6 months in standing time (55.7%, not significant), walking distance (33.9%, not significant), and 50-yard walking time (24.2%, p<0.05). Paget’s patients with coexistent joint disease had less severe pain and bone disease at baseline than those without coexistent joint disease, and responded less well to pamidronate, although they did have significant improvement in ALP levels. Radiographic assessment for coexisting joint disease prior to treatment might improve prognostication from the patient’s point of view, and improve treatment compliance.
Literatur
1.
Zurück zum Zitat Barker DJP (1984) The epidemiology of Paget’s disease of bone. Br Med Bull 40:396–400PubMed Barker DJP (1984) The epidemiology of Paget’s disease of bone. Br Med Bull 40:396–400PubMed
2.
Zurück zum Zitat Tiegs RD (1997) Paget’s disease of bone: indications for treatment and goals of therapy. Clin Ther 19:1309–1329CrossRefPubMed Tiegs RD (1997) Paget’s disease of bone: indications for treatment and goals of therapy. Clin Ther 19:1309–1329CrossRefPubMed
3.
Zurück zum Zitat Hamdy RC, Moore S, LeRoy J (1993) Clinical presentation of Paget’s disease of the bone in older patients. South Med J 86:1097–1100PubMed Hamdy RC, Moore S, LeRoy J (1993) Clinical presentation of Paget’s disease of the bone in older patients. South Med J 86:1097–1100PubMed
4.
Zurück zum Zitat Winfield J, Stamp TC (1984) Bone and joint symptoms in Paget’s disease. Ann Rheum Dis 43:769–773PubMed Winfield J, Stamp TC (1984) Bone and joint symptoms in Paget’s disease. Ann Rheum Dis 43:769–773PubMed
5.
Zurück zum Zitat Bombassei GJ, Yocono M, Raisz LG (1994) Effects of intravenous pamidronate therapy on Paget’s disease of bone. Am J Med Sci 308:226–233PubMed Bombassei GJ, Yocono M, Raisz LG (1994) Effects of intravenous pamidronate therapy on Paget’s disease of bone. Am J Med Sci 308:226–233PubMed
6.
Zurück zum Zitat Wimalawansa SJ, Gunasekara RD (1993) Pamidronate is effective for Paget’s disease of bone refractory to conventional therapy. Calcif Tissue Int 53:237–241PubMed Wimalawansa SJ, Gunasekara RD (1993) Pamidronate is effective for Paget’s disease of bone refractory to conventional therapy. Calcif Tissue Int 53:237–241PubMed
7.
Zurück zum Zitat Gutteridge DH, Retallack RW, Ward LC et al. (1996) Clinical, biochemical, hematalogic, and radiographic responses in Paget’s disease following intravenous pamidronate disodium: a 2-year study. Bone 19:387–394CrossRefPubMed Gutteridge DH, Retallack RW, Ward LC et al. (1996) Clinical, biochemical, hematalogic, and radiographic responses in Paget’s disease following intravenous pamidronate disodium: a 2-year study. Bone 19:387–394CrossRefPubMed
8.
Zurück zum Zitat Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ (1999) Effect of multiple intravenous pamidronate courses in Paget’s disease of bone. Rev Rhum (Engl Ed) 66:467–476 Trombetti A, Arlot M, Thevenon J, Uebelhart B, Meunier PJ (1999) Effect of multiple intravenous pamidronate courses in Paget’s disease of bone. Rev Rhum (Engl Ed) 66:467–476
9.
Zurück zum Zitat Lyles KW, Lammers JE, Shipp KM et al. (1995) Functional and mobility impairments associated with Paget’s disease of bone. J Am Geriatr Soc 43:502–506PubMed Lyles KW, Lammers JE, Shipp KM et al. (1995) Functional and mobility impairments associated with Paget’s disease of bone. J Am Geriatr Soc 43:502–506PubMed
10.
Zurück zum Zitat Fitton A, McTavish D (1991) Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289–318PubMed Fitton A, McTavish D (1991) Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41:289–318PubMed
11.
Zurück zum Zitat Flores RH, Hochberg MC (1998) Definition and classification of osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. New York, Oxford University Press, 1–12 Flores RH, Hochberg MC (1998) Definition and classification of osteoarthritis. In: Brandt KD, Doherty M, Lohmander LS, eds. Osteoarthritis. New York, Oxford University Press, 1–12
12.
Zurück zum Zitat Ibbertson HK, Henley JW, Fraser TR et al. (1979) Paget’s disease of bone – clinical evaluation and treatment with diphosphonate. Aust NZ J Med 9:31–35 Ibbertson HK, Henley JW, Fraser TR et al. (1979) Paget’s disease of bone – clinical evaluation and treatment with diphosphonate. Aust NZ J Med 9:31–35
13.
Zurück zum Zitat Kanis JA (1998) Pathophysiology and treatment of Paget’s disease of bone, 2nd edn. London, Martin Dunitz, 111–113 Kanis JA (1998) Pathophysiology and treatment of Paget’s disease of bone, 2nd edn. London, Martin Dunitz, 111–113
Metadaten
Titel
Patterns of pain in Paget’s disease of bone and their outcomes on treatment with pamidronate
verfasst von
Sreekanth Vasireddy
Amruta Talwalkar
Hazel Miller
Rakesh Mehan
David R. Swinson
Publikationsdatum
01.12.2003
Verlag
Springer-Verlag
Erschienen in
Clinical Rheumatology / Ausgabe 6/2003
Print ISSN: 0770-3198
Elektronische ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-003-0762-x

Weitere Artikel der Ausgabe 6/2003

Clinical Rheumatology 6/2003 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Blutdrucksenkung könnte Uterusmyome verhindern

Frauen mit unbehandelter oder neu auftretender Hypertonie haben ein deutlich erhöhtes Risiko für Uterusmyome. Eine Therapie mit Antihypertensiva geht hingegen mit einer verringerten Inzidenz der gutartigen Tumoren einher.

„Jeder Fall von plötzlichem Tod muss obduziert werden!“

17.05.2024 Plötzlicher Herztod Nachrichten

Ein signifikanter Anteil der Fälle von plötzlichem Herztod ist genetisch bedingt. Um ihre Verwandten vor diesem Schicksal zu bewahren, sollten jüngere Personen, die plötzlich unerwartet versterben, ausnahmslos einer Autopsie unterzogen werden.

Hirnblutung unter DOAK und VKA ähnlich bedrohlich

17.05.2024 Direkte orale Antikoagulanzien Nachrichten

Kommt es zu einer nichttraumatischen Hirnblutung, spielt es keine große Rolle, ob die Betroffenen zuvor direkt wirksame orale Antikoagulanzien oder Marcumar bekommen haben: Die Prognose ist ähnlich schlecht.

Schlechtere Vorhofflimmern-Prognose bei kleinem linken Ventrikel

17.05.2024 Vorhofflimmern Nachrichten

Nicht nur ein vergrößerter, sondern auch ein kleiner linker Ventrikel ist bei Vorhofflimmern mit einer erhöhten Komplikationsrate assoziiert. Der Zusammenhang besteht nach Daten aus China unabhängig von anderen Risikofaktoren.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.